MYC and chronic myelogenous leukemia, BCR-ABL1 positive: MYCMI-7 also showed potent dose-dependent inhibition of growth of four primary patient-derived AML cell cultures as well as of established AML/CML cell lines, with GI50 ranging from 0.15 to 1.3 μmol/L, and were in all cases more efficient than the MYC:MAX inhibitor 10058-F4, the bromodomain inhibitor JQ1, and cisplatin (the latter used in one case; Fig. 6B and C).